Rituxan Plus FavId (Idiotype Vaccine) for Low-grade Non-Hodgkin's Lymphoma
NCT00041730 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90
Last updated 2009-09-30
Summary
The purpose of this study is to evaluate the ability of patients treated with Rituxan® plus FavId™ and GM-CSF to mount an immune response (humoral and/or cellular) to KLH and their idiotype.
Conditions
- Non-Hodgkin's Lymphoma
Interventions
- BIOLOGICAL
-
Id-KLH
Sponsors & Collaborators
-
Favrille
lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2002-07-31
Countries
- United States
Study Locations
More Related Trials
-
Vaccine Therapy and Sargramostim Compared With Placebo and Sargramostim Following Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
NCT00089115 ·Status: TERMINATED ·Phase: PHASE3
-
Rituximab and CVP Plus Interferon for Follicular Non Hodgkins Lymphoma (NHL)
NCT00842114 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma
NCT00193492 ·Status: COMPLETED ·Phase: PHASE2
-
Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients
NCT00057447 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma
NCT00251394 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodgkin's Lymphoma (MK-3475-174/IMDZ-G142)
NCT02501473 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma
NCT00091676 ·Status: UNKNOWN ·Phase: PHASE3
-
Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma
NCT00141700 ·Status: TERMINATED ·Phase: PHASE2
-
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
NCT07225439 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)
NCT00168740 ·Status: COMPLETED ·Phase: PHASE3
-
Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma
NCT00117156 ·Status: COMPLETED ·Phase: PHASE2
-
Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma
NCT01682044 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab Plus MG4101 Indolent CD20-positive Non-Hodgkin Lymphoma (NHL)
NCT03578198 ·Status: TERMINATED ·Phase: PHASE2
-
Vaccine Therapy and Sargramostim After Rituximab in Treating Patients With Refractory or Progressive Non-Hodgkin's Lymphoma
NCT00071955 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma
NCT00301795 ·Status: TERMINATED ·Phase: PHASE2
-
Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma
NCT00510471 ·Status: TERMINATED ·Phase: PHASE2
-
Rituximab in Treating Patients With Follicular Non-Hodgkin's Lymphoma
NCT00227695 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of MabThera/Rituxan (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma
NCT01392716 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab and Cyclophosphamide Followed by Vaccine Therapy in Treating Patients With Relapsed Hodgkin Lymphoma
NCT00134082 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma
NCT00048555 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma
NCT00177554 ·Status: COMPLETED ·Phase: PHASE2
-
An Observational Study of First-Line Maintenance Rituximab (MabThera/Rituxan) in Participants With Follicular Non-Hodgkin's Lymphoma
NCT01684865 ·Status: COMPLETED
-
A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis
NCT00210340 ·Status: WITHDRAWN ·Phase: PHASE1
-
Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma
NCT00112931 ·Status: COMPLETED ·Phase: PHASE3
-
Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Adults
NCT01809600 ·Status: COMPLETED